Li M, Fang Y, Yao M, Yu W R, Ni T, Gu C, Yang P G, Mao Z G
Department of Burns and Plastic Surgery, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 201999, China.
Zhonghua Shao Shang Za Zhi. 2016 Jul 20;32(7):389-95. doi: 10.3760/cma.j.issn.1009-2587.2016.07.002.
To investigate the effects of transforming growth factor β1 (TGF-β1) receptor inhibitor SD-208 on human hypertrophic scar and its mechanisms.
Scar fibroblasts were isolated from deprecated human hypertrophic scar tissue and then sub-cultured. Cells of the fifth passage were used in the following experiments. (1) Cells were divided into blank control group (BC) and 0.5, 1.0, 3.0, and 5.0 μmol/L SD-208 groups according to the random number table (the same grouping method below), with 6 wells in each group. Cells in group BC were added with 1 μL phosphate buffer solution, while cells in the latter four groups were added with 0.5, 1.0, 3.0, and 5.0 μmol/L SD-208, respectively. After being cultured for 12 hours, the proliferation activity of cells was detected by cell counting kit 8 and microplate reader (denoted as absorbance value). Suitable amount of substance concentration of SD-208 according to the results of proliferation activity of cells was chosen for the following experiments. (2) Another batch of cells were divided into group BC and 1, 3 μmol/L SD-208 groups and treated as in (1), with 8 wells in each group. The number of migration cells was detected by transwell method. (3) Another batch of cells were grouped and treated as in (2), and the microfilament morphology of cells was observed by rhodamine-phalloidin staining. (4) Another batch of cells were grouped and treated as in (2), and the protein expression of TGF-β1 was assessed with Western blotting. (5) Forty-eight BALB/c nude mice were divided into normal saline group (NS) and 1 μmol/L SD-208 group, and one longitudinal incision with length of 1 cm was made on their back. Then human hypertrophic scar tissue was embedded into the incision. On post injury day 7, multipoint injection of NS in a volume of 0.05 mL was performed in wounds of rats in group NS, while rats in 1 μmol/L SD-208 group were given 0.05 mL 1 μmol/L SD-208, once a day. On the day 0 (the same day), 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 post first time of injection, the weight of 8 nude mice was weighed by electronic scale, and scar area was measured by vernier caliper and the ratio of rest scar area was calculated. (6) In week 1, 2, and 3 post first time of injection, the protein expression of TGF-β1 of human hypertrophic scar tissue was assessed with Western blotting. Data were processed with one-way analysis of variance and two independent-sample t test.
(1) The proliferation activity of cells in group BC, 0.5, 1.0, 3.0, and 5.0 μmol/L SD-208 groups was respectively 1.00±0.03, 0.90±0.08, 0.68±0.11, 0.54±0.04, and 0.42±0.09, and the proliferation activity of cells in 0.5, 1.0, 3.0, and 5.0 μmol/L SD-208 groups was significantly lower than that in group BC (with t values from 2.9 to 22.1, P<0.05 or P<0.01). (2) The number of migration cells in 1, 3 μmol/L SD-208 groups was significantly less than that in group BC (with t values respectively 6.5 and 6.4, P values below 0.01). (3) Compared with that in group BC, fluorescence intensity of microfilaments of cells in 1, 3 μmol/L SD-208 groups was attenuated, and the pseudopod extended less. (4) The protein expressions of TGF-β1 of cells in group BC and 1, 3 μmol/L SD-208 groups were respectively 1.00±0.08, 0.80±0.08, and 0.61±0.05, and the protein expressions of TGF-β1 of cells in 1, 3 μmol/L SD-208 groups were significantly lower than those in group BC (with t values respectively 4.0 and 9.2, P values below 0.01). (5) The weights of nude mice in group NS and 1 μmol/L SD-208 group were similar on each time day (with t values from 0.2 to 1.1, P values above 0.05). The ratios of rest scar area of nude mice in two groups were decreased along with the injection time, and the ratios of rest scar area of nude mice in 1 μmol/L SD-208 group were significantly less than those in group NS from the day 6 to 20 post first time of injection (with t values from 1.8 to 15.9, P<0.05 or P<0.01). In week 1, 2, and 3 post first time of injection, the protein expressions of TGF-β1 of human hypertrophic scar tissue in nude mice in two groups showed a tendency of decrease, and the protein expressions of TGF-β1 of human hypertrophic scar tissue in nude mice in 1 μmol/L SD-208 group were significantly lower than those in group NS (with t values from 6.2 to 19.1, P values below 0.01).
SD-208 has significant inhibition effect on human hypertrophic scars, and the mechanism is correlated to the inhibition of protein expression of endogenous TGF-β1.
探讨转化生长因子β1(TGF-β1)受体抑制剂SD-208对人增生性瘢痕的影响及其机制。
从废弃的人增生性瘢痕组织中分离瘢痕成纤维细胞并传代培养,取第5代细胞进行以下实验。(1)按随机数字表法将细胞分为空白对照组(BC)和0.5、1.0、3.0、5.0 μmol/L SD-208组(以下分组方法相同),每组6孔。BC组细胞加入1 μL磷酸盐缓冲液,后四组细胞分别加入0.5、1.0、3.0、5.0 μmol/L SD-208。培养12小时后,采用细胞计数试剂盒8和酶标仪检测细胞增殖活性(以吸光度值表示)。根据细胞增殖活性结果选择合适浓度的SD-208用于后续实验。(2)另一批细胞分为BC组和1、3 μmol/L SD-208组,按(1)法处理,每组8孔。采用transwell法检测细胞迁移数量。(3)另一批细胞分组并按(2)法处理,采用罗丹明-鬼笔环肽染色观察细胞微丝形态。(4)另一批细胞分组并按(2)法处理,采用蛋白质印迹法检测TGF-β1蛋白表达。(5)将48只BALB/c裸鼠分为生理盐水组(NS)和1 μmol/L SD-208组,于其背部作一1 cm长的纵行切口,将人增生性瘢痕组织植入切口。伤后第7天,NS组大鼠伤口多点注射0.05 mL生理盐水,1 μmol/L SD-208组大鼠给予0.05 mL 1 μmol/L SD-208,每天1次。于首次注射当天(第0天)及首次注射后第2、4、6、8、10、12、14、16、18、20天,用电子天平称取8只裸鼠体重,用游标卡尺测量瘢痕面积并计算剩余瘢痕面积比值。(6)在首次注射后第1、2、3周,采用蛋白质印迹法检测人增生性瘢痕组织中TGF-β1蛋白表达。数据采用单因素方差分析和两独立样本t检验进行处理。
(1)BC组、0.5、1.0、3.0、5.0 μmol/L SD-208组细胞增殖活性分别为1.00±0.03、0.90±0.08、0.68±0.11、0.54±0.04、0.42±0.09,0.5、1.0、3.0、5.0 μmol/L SD-208组细胞增殖活性均显著低于BC组(t值为2.9~22.1,P<0.05或P<0.01)。(2)1、3 μmol/L SD-208组细胞迁移数量显著少于BC组(t值分别为6.5和6.4,P值均<0.01)。(3)与BC组相比,1、3 μmol/L SD-208组细胞微丝荧光强度减弱,伪足伸展减少。(4)BC组、1、3 μmol/L SD-208组细胞TGF-β1蛋白表达分别为1.00±0.08、0.80±0.08、0.61±0.05,1、3 μmol/L SD-208组细胞TGF-β1蛋白表达均显著低于BC组(t值分别为4.0和9.2,P值均<0.01)。(5)NS组和1 μmol/L SD-208组裸鼠各时间点体重相近(t值为0.2~1.1,P值均>0.05)。两组裸鼠剩余瘢痕面积比值均随注射时间下降,且1 μmol/L SD-208组裸鼠自首次注射后第6天至第20天剩余瘢痕面积比值均显著低于NS组(t值为1.8~15.9,P<0.05或P<0.01)。在首次注射后第1、2、3周,两组裸鼠人增生性瘢痕组织中TGF-β1蛋白表达均呈下降趋势,且1 μmol/L SD-208组裸鼠人增生性瘢痕组织中TGF-β1蛋白表达均显著低于NS组(t值为6.2~19.1,P值均<0.01)。
SD-208对人增生性瘢痕有显著抑制作用,其机制与抑制内源性TGF-β1蛋白表达有关。